Intraperitoneal Interferon-α in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.1999.5532 ◽

1999 ◽

Vol 75 (1) ◽

pp. 10-14 ◽

Author(s):

Jonathan S. Berek ◽

Maurie Markman ◽

Bette Stonebraker ◽

Samuel S. Lentz ◽

Mark D. Adelson ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Gynecologic Oncology ◽

Interferon Α ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.05.029 ◽

2018 ◽

Vol 150 (2) ◽

pp. 247-252 ◽

Author(s):

John K. Chan ◽

William Brady ◽

Bradley J. Monk ◽

Jubilee Brown ◽

Mark S. Shahin ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Clear Cell Ovarian Carcinoma

Download Full-text

A Phase II Trial of CI-958 in Recurrent Platinum-Sensitive Ovarian Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2001.6182 ◽

2001 ◽

Vol 81 (3) ◽

pp. 433-435 ◽

Author(s):

Mark A. Hoffman ◽

John A. Blessing ◽

Evelyn R. Nuñez

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive

Download Full-text

Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6–12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2004.11.037 ◽

2005 ◽

Vol 96 (3) ◽

pp. 810-817 ◽

Author(s):

Agustin A. Garcia ◽

John A. Blessing ◽

Heinz-Josef Lenz ◽

Kathleen M. Darcy ◽

Robert S. Mannel ◽

...

Keyword(s):

Clinical Trial ◽

Ovarian Carcinoma ◽

Phase Ii ◽

Gynecologic Oncology ◽

Phase Ii Clinical Trial ◽

Primary Chemotherapy ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/s0090-8258(03)00007-6 ◽

2003 ◽

Vol 89 (1) ◽

pp. 95-98 ◽

Author(s):

Mark A Hoffman ◽

John A Blessing ◽

Samuel S Lentz

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive ◽

Download Full-text

Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma—a Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/s0090-8258(03)00068-4 ◽

2003 ◽

Vol 89 (1) ◽

pp. 148-154 ◽

Author(s):

Jeffrey D Bloss ◽

Mark F Brady ◽

Shu Yuan Liao ◽

Thomas Rocereto ◽

Edward E Partridge ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Papillary Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Serous Ovarian Carcinoma ◽

Serous Papillary Carcinoma

Download Full-text

A Phase II Study of Intraperitoneal Cisplatin and Thiotepa in Residual Ovarian Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.1998.5206 ◽

1998 ◽

Vol 71 (3) ◽

pp. 410-415 ◽

Author(s):

Lynn G. Feun ◽

John A. Blessing ◽

Francis J. Major ◽

Philip J. DiSaia ◽

Ronald D. Alvarez ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

A phase II study of PAL A (NSC 224131) in patients with advanced ovarian carcinoma A Gynecologic Oncology Group study

American Journal of Clinical Oncology ◽

10.1097/00000421-198406000-00011 ◽

1984 ◽

Vol 7 (3) ◽

pp. 257-260 ◽

Author(s):

Hyman B. Muss ◽

Milan Slavik ◽

Brian Bundy ◽

Frederick B. Stehman ◽

William T. Creasman

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Advanced Ovarian Carcinoma

Download Full-text

A Phase II Trial of Gallium Nitrate (NSC #15200) in Previously Treated Ovarian Carcinoma A Gynecologic Oncology Group Study

American Journal of Clinical Oncology ◽

10.1097/00000421-199108000-00015 ◽

1991 ◽

Vol 14 (4) ◽

pp. 349-351 ◽

Author(s):

John H. Malfetano ◽

John A. Blessing ◽

Mark D. Adelson

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gallium Nitrate ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Previously Treated

Download Full-text

Intraperitoneal α-Interferon Alternating with Cisplatin in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.1999.5455 ◽

1999 ◽

Vol 74 (1) ◽

pp. 48-52 ◽

Author(s):

Jonathan S. Berek ◽

Maurie Markman ◽

John A. Blessing ◽

Paul R. Kucera ◽

Beth E. Nelson ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70331-2 ◽

2007 ◽

Vol 2007 ◽

pp. 82-83

Author(s):

J.T. Thigpen

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text